Myleran (Busulfan)

Busulfan, the active ingredient in Myleran, is an alkylating agent presented as an oral capsule for oral use. It is employed in conditioning regimens prior to hematopoietic stem cell transplantation and in the treatment of certain leukemias. GNH USA supplies Myleran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Busulfan is an alkylating antineoplastic agent used in myeloablative conditioning and leukemia treatment.

- Conditioning regimen prior to hematopoietic stem cell transplantation: provides myeloablation to facilitate donor cell engraftment. - Chronic myelogenous leukemia (historical use): used in combination therapy to achieve cytoreduction. - Acute myeloid leukemia (in combination regimens): contributes to disease control when combined with other chemotherapeutics.

Busulfan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Oral mucositis: inflammation and ulceration of the mouth lining. - Skin hyperpigmentation: darkening of the skin, especially on the face and hands. - Low blood cell counts: neutropenia, anemia, or thrombocytopenia.

Serious or Rare Side Effects: - Pulmonary fibrosis: scarring of lung tissue that can impair breathing. - Hepatic veno‑occlusive disease: blockage of small veins in the liver leading to liver dysfunction. - Seizures: neurologic events that may require anticonvulsant prophylaxis.

When prescribing Busulfan, clinicians should observe several safety measures to minimize risks. - Monitor blood counts: perform regular CBC to detect neutropenia or thrombocytopenia. - Assess liver function: check enzymes and bilirubin before and during therapy. - Evaluate pulmonary status: baseline lung function tests are recommended. - Use anticonvulsant prophylaxis: consider seizure prevention in high‑risk patients. - Avoid use in pregnancy: Busulfan is classified as Category D and may cause fetal harm. - Store at ambient temperature: keep capsules below 25°C in the original container, protected from moisture.

Busulfan interacts with several drugs that can alter its plasma concentration or toxicity profile.

Major Interactions (Avoid): - Azole antifungals (e.g., fluconazole, itraconazole): inhibit metabolism and markedly increase Busulfan exposure. - Phenytoin and carbamazepine: induce metabolism and reduce Busulfan levels, risking treatment failure.

Moderate Interactions (Monitor Closely): - Acetaminophen: may increase Busulfan exposure; monitor for toxicity. - Other alkylating agents (e.g., cyclophosphamide): additive myelosuppression risk. - Renal impairment agents: adjust dosing and monitor clearance.